StockNews.com Begins Coverage on Oncternal Therapeutics (NASDAQ:ONCT)

Stock analysts at StockNews.com started coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued to investors on Wednesday. The firm set a “hold” rating on the stock.

A number of other analysts also recently issued reports on the stock. HC Wainwright lowered their price objective on shares of Oncternal Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Monday, August 12th. Northland Securities reiterated a “market perform” rating and issued a $2.00 price target on shares of Oncternal Therapeutics in a research note on Thursday, September 12th. Northland Capmk cut shares of Oncternal Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, September 12th. Finally, Brookline Capital Management restated a “hold” rating on shares of Oncternal Therapeutics in a report on Thursday, September 12th. Four analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $20.00.

Oncternal Therapeutics Price Performance

Shares of Oncternal Therapeutics stock opened at $0.75 on Wednesday. The firm has a market cap of $2.21 million, a price-to-earnings ratio of -0.06 and a beta of 1.33. The stock’s 50-day moving average is $1.31 and its 200-day moving average is $4.68. Oncternal Therapeutics has a one year low of $0.62 and a one year high of $13.14.

Institutional Investors Weigh In On Oncternal Therapeutics

A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC acquired a new position in Oncternal Therapeutics, Inc. (NASDAQ:ONCT) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned approximately 0.84% of Oncternal Therapeutics as of its most recent SEC filing. 16.05% of the stock is currently owned by institutional investors and hedge funds.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.